Diurnal Group PLC (LON:DNL) hit a new 52-week high on Monday . The company traded as high as GBX 215.80 ($2.98) and last traded at GBX 215.80 ($2.98), with a volume of 2434 shares traded. The stock had previously closed at GBX 211 ($2.92).

Separately, Numis Securities reaffirmed a “buy” rating and set a GBX 185 ($2.56) target price on shares of Diurnal Group in a research report on Monday, December 18th.

How to Become a New Pot Stock Millionaire

The company has a market cap of $185.23 and a PE ratio of -1,070.00.

Diurnal Group (LON:DNL) last announced its earnings results on Monday, March 12th. The company reported GBX (12.70) (($0.18)) earnings per share (EPS) for the quarter.

In other Diurnal Group news, insider John Goddard purchased 10,791 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was acquired at an average cost of GBX 540 ($7.46) per share, with a total value of £58,271.40 ($80,507.60).

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/03/14/diurnal-group-dnl-sets-new-52-week-high-at-215-80.html.

Diurnal Group Company Profile

Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.

Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.